CEO Executive AssistantBelay vs Boldly is one of the most common virtual EA service comparisons for executives seeking high-quality managed support. For pharmaceutical and biotech CEOs specifically, both services occupy the premium end of the managed EA market, but they differ in meaningful ways that affect how well they serve the specific demands of life sciences executive leadership.
This comparison addresses both services honestly, covering pricing, EA quality, pharmaceutical industry fit, and what each delivers for a CEO managing clinical programs, investor relations, and regulatory obligations.
Belay: Overview for Pharmaceutical CEOs
Belay is one of the most established managed virtual EA services in the US market, founded in 2010 and serving thousands of clients across industries. Their model centers on US-based, college-educated virtual assistants matched to clients through a structured intake and matching process.
Pricing: Belay’s pricing is not publicly listed, but the market range for their EA services runs $1,800 to $5,000 per month depending on hours and service tier. Full-time equivalent support runs at the higher end of that range.
EA Quality: Belay EAs are known for professional communication standards and executive-level organizational skills. They are generalists rather than pharmaceutical specialists, which means the ramp-up period for a pharma CEO client will require deliberate onboarding investment.
Matching Process: Belay’s matching process typically takes two to four weeks. They gather detailed information about your preferences, work style, and role requirements before recommending an EA.
Replacement Policy: Belay provides replacement guarantees. If a match does not work, they rematch you. The process takes one to two weeks.
For Pharma CEOs: Belay is well-suited for pharmaceutical CEOs who prioritize professional communication quality and operational reliability over pharmaceutical-specific domain knowledge. You will need to invest in onboarding your EA on regulatory terminology and industry context, but the underlying capability is strong.
Boldly: Overview for Pharmaceutical CEOs
Boldly operates a subscription EA model that employs their assistants directly (as W-2 employees) rather than using an independent contractor model. This distinction matters for consistency and accountability. Boldly’s EAs work exclusively on their platform and are subject to Boldly’s quality standards and management oversight.
Pricing: Boldly’s pricing is more transparent than Belay’s. Their subscription plans start at approximately $1,500 per month for 10 hours per week and scale to $3,000 per month for 20 hours per week. Full-time support runs $4,800 to $6,000 per month.
EA Quality: Boldly markets their EAs as more senior and experienced than typical virtual assistant services. Their talent pool draws from professionals with corporate executive support backgrounds. Communication standards are high.
Matching Process: Boldly’s matching is faster than Belay’s, typically taking one to two weeks. Their process also emphasizes personality and work style alignment.
Replacement Policy: As a W-2 employment model, Boldly handles replacement and continuity through its employment infrastructure. If your EA is unavailable, Boldly coordinates coverage.
For Pharma CEOs: Boldly’s senior EA pool and strong communication standards make them a strong fit for pharmaceutical CEOs who need an EA that can handle investor communications, board preparation, and senior stakeholder management at a high level. Like Belay, pharmaceutical industry knowledge is not built in, but the talent foundation is strong enough to develop.
Head-to-Head: Key Comparison Points
EA Experience Level
Boldly explicitly markets their EAs as more experienced, drawing from professionals who have held senior corporate roles. Belay’s talent pool is broader, which means experience levels may vary more within their matching pool.
For pharmaceutical CEOs who need someone who can manage the complexity of executive communications without close supervision, Boldly’s senior talent positioning is an advantage.
Pricing Transparency
Boldly is more transparent about pricing, making it easier to budget and compare. Belay requires a consultation before pricing is discussed.
If you prefer to evaluate cost before entering a sales process, Boldly’s pricing model is more efficient.
Commitment Structure
Both services offer subscription models with month-to-month and annual contract options. Annual commitments typically earn a discount of 10 to 15 percent.
For pharmaceutical CEOs, annual commitments make sense if you have stable, ongoing support needs. If your workload is highly variable (for example, if your EA needs spike during NDA submissions and taper during quieter regulatory periods), verify whether either service offers flexible hour bank arrangements.
Pharmaceutical Industry Knowledge
Neither Belay nor Boldly specifically screens for pharmaceutical or biotech industry experience. Both services can accommodate pharmaceutical clients effectively, but you are working with executive generalists rather than life sciences specialists.
If pharmaceutical industry knowledge is a critical requirement, neither service may satisfy that need without significant onboarding investment. For services with pharmaceutical specialization, see best virtual EA for pharma for a broader market view.
For a full analysis of costs across service tiers, cost of EA for pharma provides detailed pricing context.
What Pharmaceutical CEOs Should Ask Either Provider
Before committing to Belay or Boldly, ask these questions in your sales consultation.
- Do you have current clients at pharmaceutical or biotech companies? Can you share what roles they support?
- What pharmaceutical or life sciences experience do the EAs you are considering for my role have?
- How do you handle confidentiality for clients in regulated industries? What NDA terms apply?
- What is your replacement turnaround time if my EA is unavailable during a critical regulatory period?
- How do you handle scope expansion if my needs spike during a high-demand period like an investor road show or NDA submission?
Research Context: What Makes EA Services Effective
Research published by Harvard Business Review highlights that the effectiveness of executive support depends less on the service brand and more on the specific match between the EA’s skills and the executive’s working style and operational needs. Both Belay and Boldly have the infrastructure to produce excellent matches. The quality of your outcome depends significantly on the detail and accuracy of your intake process.
Which Service Is Better for Pharmaceutical and Biotech CEOs?
Choose Boldly if: You want more experienced, senior-level EA talent with strong communication skills, and you value pricing transparency. Boldly’s W-2 employment model also provides slightly better continuity assurance.
Choose Belay if: You want a more established service with a longer track record, a broader talent pool, and a slightly lower entry price point. Belay’s matching process is more detailed, which can produce a better fit if you invest in the intake.
Consider alternatives if: Pharmaceutical industry knowledge is essential from day one. Neither service specializes in life sciences, and you may get better results from a boutique service or a direct search for a freelance EA with pharmaceutical experience.
Conclusion
The Belay vs Boldly comparison for pharmaceutical and biotech CEOs comes down to experience level (Boldly edges ahead), pricing transparency (Boldly again), and breadth of talent pool (Belay). Both are legitimate choices for pharmaceutical executives who need high-quality generalist EA support and are prepared to invest in onboarding. Neither provides pharmaceutical specialization out of the box, which means industry context will need to be built through your onboarding process.
Related Reading
For further context, explore Belay vs Boldly: Best Virtual EA for Automotive CEOs and Belay vs Boldly: Best Virtual EA for Construction & Architecture CEOs.